SML3453
MGCD0103
≥95% (HPLC)
别名:
MGCD, MGCD 0103, MGCD-0103, Mocetinostat, N-(2-Amino-phenyl)-4-((4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl)-benzamide
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C23H20N6O
化学文摘社编号:
分子量:
396.44
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥95% (HPLC)
Form:
powder
Quality Segment
assay
≥95% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
SMILES string
N(Cc3ccc(cc3)C(=O)Nc4c(cccc4)N)c1nc(ccn1)c2cnccc2
InChI
1S/C23H20N6O/c24-19-5-1-2-6-21(19)28-22(30)17-9-7-16(8-10-17)14-27-23-26-13-11-20(29-23)18-4-3-12-25-15-18/h1-13,15H,14,24H2,(H,28,30)(H,26,27,29)
InChI key
HRNLUBSXIHFDHP-UHFFFAOYSA-N
Biochem/physiol Actions
MGCD0103 (Mocetinostat) is an orally active, potent and subtype-selective histone deacetylase (HDAC) inhibitor (IC50: class I HDAC1/2/3 = 0.15/0.29/1.66 μM, class IV HDAC11 = 0.59 μM, HDAC4/5/7/8 >10 μM) that effectively inhibits cellular HDAC activity (IC50 = 450 nM; Du145, HCT15, HCT116), resulting in an upregulated acetylation of histone H3 and H4, but not that of tubulin. MGCD0103 daily orally administration (60-120 mg/kg) is efficacious against A549 & H1437 tumor growth in mice in vivo.
Orally active, potent and HDAC1/2/3/11 subtype-selective histone deacetylase inhibitor with anti-tumor efficacy in mice in vivo.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable